Patent application number | Description | Published |
20080213220 | Cancer-targeted viral vectors - The present invention relates to viral vectors that are targeted to cancer cells. The viral vectors of the invention are adenoviruses having a PEG-3 promoter driving the expression of the viral genes E1A and E1B. The PEG-3 promoter exhibits increased activity in malignant cells. Adenoviruses of the invention show increased replication in malignant cells, thereby producing a cytopathic effect. The viral vectors of the invention further comprise additional genes of interest, and/or may have altered capsid proteins that may enhance infection of and/or target infection to cancer cells. Additional cell types derived from diseased states in which the PEG-3 promoter is selectively active are also therapeutic targets of the viral vectors of the instant invention including those generating allergic, autoimmune and inflammatory responses. | 09-04-2008 |
20110313028 | SUPPRESSOR OF AP-1 - Methods, compositions, and therapeutic products for use in the field of oncology and specifically, for the treatment of cancer and other diseases in which SARI is ameliorative or therapeutic and/or small molecule screening for anti-cancer drugs are provided. Cancer specific gene expression using the CCN1 promoter, which is negatively regulated by SARI, for targeting therapeutic molecules in tumors is also provided. | 12-22-2011 |
20120195935 | MICROBUBBLE ASSISTED VIRAL DELIVERY - Microbubble-assisted delivery of viruses is disclosed. In particular, methods for targeting a virus to cancer cells in an immunocompetent animal by administering a selectively replicating virus to the immunocompetent animal and disrupting the microbubbles in a location of the animal comprising cancer cells are provided. The virus is encompassed in a suspension of microbubbles, and the surface of the suspension does not include any virus. A suspension of microbubbles comprising a selectively replicating virus that is encompassed in a suspension of microbubbles, which does not include any virus on the surface of the suspension, is also provided. | 08-02-2012 |
20130028899 | TREATMENT OF CANCER BY INHIBITING ACTIVITY OR EXPRESSION OF LATE SV-40 FACTOR - Inhibitors of Late SV-40 Factor (LSF) are used to treat cancers such as hepatocellular carcinoma (HCC). In particular, small molecule chemical LSF inhibitors are employed. In addition, the activity and/or pattern of expression of LSF may is used to diagnose cancer, to characterize the cancer (e.g. stage, grade, prognosis, etc.) and also to develop suitable protocols for cancer treatment. | 01-31-2013 |
20160101193 | USE OF A TRUNCATED CCN1 PROMOTER FOR CANCER DIAGNOSTICS, THERAPEUTICS AND THERANOSTICS - Recombinant vectors in which expression of one or more elements (e.g. genes required for viral replication, detectable imaging agents, therapeutic agents, etc.) is driven by a truncated CCN 1 cancer selective promoter (tCCN1-Prom) are provided, as are cells and transgenic animals that contain such vectors. The vectors are used in cancer therapy and/or diagnostics, and the transgenic mice are used to monitor cancer progression, e.g. in screening assays. | 04-14-2016 |
20160106866 | TRIPARTITE CANCER THERANOSTIC NUCLEIC ACID CONSTRUCTS - The presently disclosed subject matter generally relates to genetic constructs and methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols. In particular, the presently disclosed subject matter relates to tripartite cancer theranostic nucleic acid constructs that permit simultaneous cancer specific viral replication, expression of a diagnostic gene product, and expression of a therapeutic gene. | 04-21-2016 |
20160108101 | RECOMBINANT CANCER THERAPEUTIC CYTOKINE - Recombinant therapeutic cytokines (“therakines”) for the treatment of cancer are provided. The recombinant therakines include a truncated region of MDA-7/TL-24 (“M4”) not normally found in nature that has anti-cancer activity and a secretory signal which causes secretion of the therakine from plasmid/virus transduced normal and cancer cells and interaction of the therakine to MDA-7/IL-24 receptors on adjacent, neighboring and distant cancer cells. Therakine interaction results in bystander killing of the target cancer cell as well as adjacent, neighboring and distant cancer cells. | 04-21-2016 |
20160108429 | PEG-PROM MEDIATED SURFACE EXPRESSION OF AVIDIN/STREPTAVIDIN - The presently disclosed subject matter relates to compositions and methods directed to cancer theranostic nucleic acid constructs that permit simultaneous cancer-specific viral replication, expression of a diagnostic gene product, and expression of a therapeutic gene. | 04-21-2016 |